1) Findings: Insights and developments globally on the subject of cancer.
2) Companies: Updates and progress reports on Consortium member companies.
3) Industry: Important developments from throughout the field of cancer.
The Food and Drug Administration (FDA) has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla) to treat some women with HER2-positive breast cancer. Ado-trastuzumab, also called T-DM1, was initially approved by FDA more […]
The potential benefits of vaccines are twofold: In addition to directly protecting those who get the vaccine, they also protect those who don’t. The latter, a phenomenon called herd immunity, occurs as […]
Avelas Biosciences, a California-based clinical-stage oncology company, is developing AVB-620, a novel drug-device combination product for use during cancer surgery. AVB-620 works to improve surgery by detecting cancer in real-time and has […]
Chaos can be surprisingly orderly. While cancer is characterized by uncontrolled cell growth, that growth is, nevertheless, the result of a very particular cascade of events, from carcinogen exposure to genetic mutations. […]
Despite all of the advancements in cancer research and cures, there is one major aspect of the disease that is as under-discussed as it is controversial: patient cost. While the road to […]
MiraDx, a Los Angeles-based company, is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant. They are developing answers by applying their novel […]
“HER2 is a gene that codes for a protein sitting on the cell surface and sending signals for the cell to grow and divide,” explains Dr. Daniel Haber, Director at Massachusetts General Hospital […]
For many children with advanced forms of neuroblastoma, receiving two separate stem cell transplants as part of their treatment is more beneficial than receiving one. That’s according to the results of an NCI-supported clinical trial […]
